CA125 in ovarian cancer
Open accessAbstract
A quarter of a century since its discovery, circulating CA125 antigen is recommended for clinical use in the USA for ovarian cancer screening of high-risk women with ovaries, despite its limited sensitivity and specificity. Recent findings suggest that CA125 might also serve as a predictive marker for pre-invasive ovarian carcinoma. Methods to quantify circulating CA125 evolved toward sensitive and reliable double-determinant ELISA assays. The CA125 gene, MUC16, was cloned 20 years after the protein discovery and revealed a very complex and unusual glycoprotein structure, suggesting an immunological role. Recent evidence points toward CA125 function in the induction of materno-fetal tolerance through the alteration of natural killer phenotype. Two receptors for CA125 have been described: mesothelin and galectin-1. The specific location and functional proprieties of CA125 make it a therapeutic target of choice; clinical trials have demonstrated that anti-CA125 injections are well tolerated and suggest a potential survival benefit.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Serum CA125 is not a valuable marker for the diagnosis of malignant transformation of endometriosis.
“Although serum CA125 it is an important indicator in advanced-stage ovarian cancer, where its value increases along with tumor size and is useful for predicting responses to chemotherapy, disease progression and recurrence, serum CA125 does not seem to be a valuable marker for the diagnosis of malignant transformation of endometriosis [18,34].”
From Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review (2024) · cites this paper as [18]
The Introduction (page unavailable) says CA125 can be elevated in benign endometriosis, and the Executive Summary (page unavailable) says it has inadequate specificity for malignancy. These points support a concern about using CA125 to distinguish benign from malignant disease, but the paper does not specifically assess its value for diagnosing malignant transformation of endometriosis. (LLM, conf=0.81)
Experimental — accuracy not yet measuredThere is no specific tumor marker for the malignant transformation of endometriosis.
“Currently, there is no specific tumor marker for the malignant transformation of endometriosis.”
From Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review (2024) · cites this paper as [18]
The Introduction (page unavailable) says CA125 can be elevated in benign endometriosis, and the Executive Summary (page unavailable) describes its specificity for malignancy as inadequate. This supports the narrower point that CA125 cannot specifically identify malignancy in endometriosis, but the paper does not establish that no tumor marker is specific for malignant transformation of endometriosis. (LLM, conf=0.84)
Experimental — accuracy not yet measuredSerum CA125 is an important indicator in advanced-stage ovarian cancer, where its value increases along with tumor size and is useful for predicting responses to chemotherapy, disease progression and recurrence.
“Although serum CA125 it is an important indicator in advanced-stage ovarian cancer, where its value increases along with tumor size and is useful for predicting responses to chemotherapy, disease progression and recurrence, serum CA125 does not seem to be a valuable marker for the diagnosis of malignant transformation of endometriosis [18,34].”
From Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review (2024) · cites this paper as [18]
The Introduction (page unavailable) says serum CA125 changes correlate with ovarian tumor progression or regression, predict outcome during cytostatic treatment, and can precede recurrence. It does not establish that CA125 rises with tumor size, so that part of the attributed claim is unsupported. (LLM, conf=0.85)
Experimental — accuracy not yet measuredOvarian and/or pelvic endometriosis is associated with approximately 42% of endometrioid ovarian cancer.
“Ovarian and/or pelvic endometriosis is associated with approximately 42% of endometrioid ovarian cancer [18,19,20,21].”
From Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review (2024) · cites this paper as [18]
The Introduction discusses ovarian cancer and the possible fallopian-tube origin of serous tumors, while the Conclusions references mention endometriosis in relation to CA125. Searches for endometrioid ovarian cancer, endometriosis, and 42% found no passage in our copy reporting the claimed association or percentage. (LLM, conf=0.72)
Experimental — accuracy not yet measuredLarger cohorts have shown an increased risk of cancer in women with endometriosis.
“Larger cohorts have shown an increased risk of cancer in women with endometriosis [18,34].”
From Malignancy in Abdominal Wall Endometriosis: Is There a Way to Avoid It? A Systematic Review (2024) · cites this paper as [18]
The Introduction (page not provided) mentions endometriosis only as a benign condition associated with elevated CA125. A search for endometriosis and cancer risk found no passage reporting that larger cohorts observed increased cancer risk in women with endometriosis. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 134 · Cited by 220
Research works printed but not linked: 1
- [119]Wagner U, Kohler S, Reinartz S, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res. 2001;7:1154–1162. [PubMed] [Google Scholar]
- Authors
- Scholler, N., & Urban, N.
- Affiliations
- University of Pennsylvania (US)
- Fred Hutch Cancer Center (US)
- Venue
- Biomarkers in Medicine
- Publisher
- Informa UK Limited
- Published
- 2007-12
- Volume
- 1
- Issue
- 4
- Pages
- 513-523
- ISSN
- 1752-0363 (ISSN-L)
- 1752-0371
- PMC
- PMC2872496
- OpenAlex
- W2117845602
- Cited by
- 220
- References
- 134
- Citations by year
- 2026: 8 · 2025: 21 · 2024: 23 · 2023: 20 · 2022: 18 · 2021: 30 · 2020: 19 · 2019: 9 · 2018: 13 · 2017: 9 · 2016: 8 · 2015: 8 · 2014: 13 · 2013: 3 · 2012: 4
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biomarkers in Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5p50ca083636-15)
- National Cancer Institute (P50-CA083636)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- CA125, ovarian cancer, tumor markers, ovarian cancer screening, glycoprotein structure, natural killer cells, mesothelin, galectin-1, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
